PDF herunterladen
Exp Clin Endocrinol Diabetes 2020; 128(11): 731-736
DOI: 10.1055/a-0895-5138
Article

Serum Myeloperoxidase, C-reactive Protein and α1-acid Glycoprotein: Insights about Cardiovascular Risk in End-stage Renal Disease

Cristiane Rickli
1   State University of Ponta Grossa – UEPG, Ponta Grossa-PR, Brazil
,
Danielle Cristyane Kalva Borato
1   State University of Ponta Grossa – UEPG, Ponta Grossa-PR, Brazil
,
Anderson José de Melo E Silva
1   State University of Ponta Grossa – UEPG, Ponta Grossa-PR, Brazil
,
Adriana Fatima Menegat Schuinski
1   State University of Ponta Grossa – UEPG, Ponta Grossa-PR, Brazil
,
Gustavo Henrique Frigieri Vilela
2   Braincare Technological Development and Innovation LTDA, São Carlos-SP, Brazil
,
José Carlos Rebuglio Vellosa
1   State University of Ponta Grossa – UEPG, Ponta Grossa-PR, Brazil
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Background Cardiovascular disease (CVD) is the leading cause of death in patients with end-stage renal disease (ESRD). Elevated serum concentrations of myeloperoxidase (MPO) are associated with an increased risk of developing CVD. The objective of this study was to evaluate serum MPO levels, as well as other laboratory parameters, in individuals with ESRD, with and without CVD, undergoing hemodialysis.

Methods 80 volunteers were admitted, divided into the following groups: control group (CON): 20 individuals without chronic kidney disease (CKD); ESRD group: 45 individuals with CKD stage V and ESRD/CVD group: 15 individuals with CKD stage V and with CVD. The following biomarkers were evaluated: MPO, High sensitivity C-reactive protein (hs-CRP) and α1-acid glycoprotein, following the manufacturer's guidelines in the package inserts. The data were processed through the statistical software SPSS 20.0®.

Results The level of MPO for the CON group was 84 ng/mL (73–87 ng/mL), for the ESRD group 77 ng/mL (11–89 ng/mL) and for the ESRD/CVD group 21 ng/mL (8–47 ng/mL), with a significant statistical difference of the ESRD/CVD group from the CON and ESRD groups (p<0.001). For the parameters hs-CRP and α1-acid glycoprotein a statistical difference between the ESRD and ESRD/CVD groups from the CON group (p<0.0001) was observed, but not between the ESRD and ESRD/CVD groups.

Conclusion It is suggested that further studies should be performed to define the potential role of MPO as a cardiovascular risk marker for patients with ESRD on hemodialysis.

Key words

cardiovascular disease - myeloperoxidase - α1-acid glycoprotein - C-reactive protein.


Publikationsverlauf

Eingereicht: 08. September 2018
Eingereicht: 01. April 2019

Angenommen: 05. April 2019

Artikel online veröffentlicht:
02. Mai 2019

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Peres LAB, Biela R, Herrmann M. et al. Estudo epidemiológico da doença renal crônica terminal no oeste do Paraná: Uma experiência de 878 casos atendidos em 25 anos. J Bras Nefrol 2010; 32: 51-56
    CrossrefPubMedGoogle Scholar
  • 2 Khatiwada S, KC R, Gautam S. et al. Thyroid dysfunction and dyslipidemia in chronic kidney disease patients. BMC Endocr Disord 2015; 15: 65
    CrossrefPubMedGoogle Scholar
  • 3 Collins AJ. Cardiovascular mortality in end-stage renal disease. Am J Med Sci 2003; 325: 163-167
    CrossrefPubMedGoogle Scholar
  • 4 Sarnak MJ, Levey AS, Schoolwerth AC. et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the american heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003; 108: 2154-2169
    CrossrefPubMedGoogle Scholar
  • 5 Stenvinkel P, Carrero JJ, Axelsson J. et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle?. Clin J Am Soc Nephrol 2008; 3: 505-521
    CrossrefPubMedGoogle Scholar
  • 6 Kendrick J, Chonchol MB. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol 2008; 4: 672-681
    CrossrefPubMedGoogle Scholar
  • 7 Coresh J, Byrd-Holt D, Astor BC. et al. Chronic kidney disease awareness, prevalence, and trends among U.S. Adults, 1999 to 2000. J Am Soc Nephrol 2005; 16: 180-188
    CrossrefPubMedGoogle Scholar
  • 8 Korevaar JC, Van Manen JG, Dekker FW. et al. Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol 2004; 15: 2916-2922
    CrossrefPubMedGoogle Scholar
  • 9 Sharif MR, Chitsazian Z, Moosavian M. et al. Immune disorders in hemodialysis patients. Iran J Kidney Dis 2015; 9: 84-96
    PubMedGoogle Scholar
  • 10 Meuwese CL, Stenvinkel P, Dekker FW. et al. Monitoring of inflammation in patients on dialysis: Forewarned is forearmed. Nat Rev Nephrol 2011; 7: 166-176
    CrossrefPubMedGoogle Scholar
  • 11 Zhang W, He J, Zhang F. et al. Prognostic role of C-reactive protein and interleukin-6 in dialysis patients: A systematic review and meta-analysis. J Nephrol 2013; 26: 243-253
    CrossrefPubMedGoogle Scholar
  • 12 Menon V, Wang X, Greene T. et al. Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis 2003; 42: 44-52
    CrossrefPubMedGoogle Scholar
  • 13 Busch M, Franke S, Müller A. et al. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int 2004; 66: 338-347
    CrossrefPubMedGoogle Scholar
  • 14 Recio-Mayoral A, Banerjee D, Streather C. et al. Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease - A cross-sectional study of predialysis, dialysis and kidney-transplantation patients. Atherosclerosis 2011; 216: 446-451
    CrossrefPubMedGoogle Scholar
  • 15 Shemirani H, Tavakol S, Atapoor A. et al. The role of inflammatory processes in occurrence of left ventricular failure in patients with chronic kidney disease. Adv Biomed Res 2017; 6: 13
    CrossrefPubMedGoogle Scholar
  • 16 Kamori T, Nonaka A, Maruyama T. et al. Effect of clarithromycin on alpha1-acid glycoprotein levels in normal and diabetic rats. Res Commun Mol Pathol Pharmacol 1998; 101: 233-240
    PubMedGoogle Scholar
  • 17 Scirè A, Baldassarre M, Galeazzi R. et al. Fibrillation properties of human α1-acid glycoprotein. Biochimie 2013; 95: 158-166
    CrossrefPubMedGoogle Scholar
  • 18 Arsenault BJ, Stroes ESG, Boekholdt SM. Is myeloperoxidase a useful marker to predict the risk of cardiovascular events?. Curr Cardiovasc Risk Rep 2009; 3: 137-143
    CrossrefPubMedGoogle Scholar
  • 19 Nicholls SJ, Hazen SL. Myeloperoxidase, modified lipoproteins, and atherogenesis. J Lipid Res 2008; 50: S346-S351
    CrossrefPubMedGoogle Scholar
  • 20 Madhusudhana Rao A, Anand U, Anand CV. Myeloperoxidase in chronic kidney disease. Indian J Clin Biochem 2011; 26: 28-31
    CrossrefPubMedGoogle Scholar
  • 21 Caimi G, Carollo C, Montana M. et al. Elastase, myeloperoxidase, nitric oxide metabolites and oxidative status in subjects with clinical stable chronic renal failure on conservative treatment. Clin Hemorheol Microcirc 2009; 43: 253-258
    CrossrefPubMedGoogle Scholar
  • 22 Wang AYM, Lam CWK, Chan IHS. et al. Prognostic value of plasma Myeloperoxidase in ESRD patients. Am J Kidney Dis 2010; 56: 937-946
    CrossrefPubMedGoogle Scholar
  • 23 Kalantar-Zadeh K, Brennan ML, Hazen SL. Serum Myeloperoxidase and Mortality in Maintenance Hemodialysis Patients. Am J Kidney Dis 2006; 48: 59-68
    CrossrefPubMedGoogle Scholar
  • 24 Afshinnia F, Zeng L, Byun J. et al. Myeloperoxidase levels and its product 3-chlorotyrosine predict chronic kidney disease severity and associated coronary artery disease. Am J Nephrol 2017; 46: 73-81
    CrossrefPubMedGoogle Scholar
  • 25 Wu CC, Chen JS, Wu WM. et al. Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes. Nephrol Dial Transplant 2005; 20: 1134-1139
    CrossrefPubMedGoogle Scholar
  • 26 Zhang R, Brennan M-L, Fu X. et al. Association between myeloperoxidase levels and risk of coronary artery disease. Jama 2001; 286: 2136-2142
    CrossrefPubMedGoogle Scholar
  • 27 Baldus S, Heeschen C, Meinertz T. et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003; 108: 1440-1445
    CrossrefPubMedGoogle Scholar
  • 28 Rudolph V, Goldmann BU, Bös C. et al. Diagnostic value of MPO plasma levels in patients admitted for suspected myocardial infarction. Int J Cardiol 2011; 153: 267-271
    CrossrefPubMedGoogle Scholar
  • 29 Hasanpour Z, Javanmard S, Gharaaty M. et al. Association between serum myeloperoxidase levels and coronary artery disease in patients without diabetes, hypertension, obesity, and hyperlipidemia. Adv Biomed Res 2016; 5: 103
    CrossrefPubMedGoogle Scholar
  • 30 Kubala L, Lu G, Baldus S. et al. Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease. Clin Chim Acta 2008; 394: 59-62
    CrossrefPubMedGoogle Scholar
  • 31 Artunc F, Nowak A, Müller C. et al. Mortality prediction using modern peptide biomarkers in hemodialysis patients - A comparative analysis. Kidney Blood Press Res 2014; 39: 563-572
    CrossrefPubMedGoogle Scholar
  • 32 Phukan RR, Goswami RK. Unusual dyslipidemia in patients with chronic kidney diseases. J Clin Diagnostic Res 2017; 11: BC01-BC04
    PubMedGoogle Scholar
  • 33 Liu Y, Ele Q. Alkaline phosphatase, ipth and bone turnover markers in chinese advanced chronic kidney disease patients. Clin Lab 2015; 61: 839-843
    PubMedGoogle Scholar
  • 34 Chang JF, Feng YF, Peng YS. et al. Combined alkaline phosphatase and phosphorus levels as a predictor of mortality in maintenance hemodialysis patients. Medicine (Baltimore) 2014; 93: 1-8
    CrossrefPubMedGoogle Scholar
  • 35 Bonomini M, Del Vecchio L, Sirolli V. et al. New treatment approaches for the anemia of CKD. Am J Kidney Dis 2016; 67: 133-142
    CrossrefPubMedGoogle Scholar
  • 36 Jung MY, Hwang SY, Hong YA. et al. Optimal hemoglobin level for anemia treatment in a cohort of hemodialysis patients. Kidney Res Clin Pract 2015; 34: 20-27
    CrossrefPubMedGoogle Scholar
  • 37 Hillege HL, Nitsch D, Pfeffer MA. et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113: 671-678
    CrossrefPubMedGoogle Scholar
  • 38 Levin A, Thompson CR, Ethier J. et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134
    CrossrefPubMedGoogle Scholar
  • 39 Cavalcante LG, Cavalcante RS, Kochi AC. et al. Left ventricular mass behaviour in hemodialysis patients during 17 years. J Bras Nefrol 2015; 37: 341-348
    CrossrefPubMedGoogle Scholar
  • 40 Tsuruya K, Eriguchi M, Yamada S. et al. Cardiorenal syndrome in end-stage kidney disease. Blood Purif 2015; 40: 337-343
    CrossrefPubMedGoogle Scholar